Latest Regulatory News

Macquarie Technology Group has reported its eleventh consecutive year of EBITDA growth, driven by strategic investments in data centre infrastructure and AI capabilities. The company is advancing its IC3 SuperWest project and has secured land for a new Sydney data centre campus.

NextEd Group reported a 13.9% revenue decline in FY25, yet maintained resilient EBITDA and strengthened its cash position, signaling a strategic reset underway to capture future growth.

NextEd Group Limited reported a 13.9% revenue decline to $95.9 million for FY25 but achieved a 53% improvement in net loss after tax, driven by cost savings and operational efficiencies. The company’s strategic repositioning includes leadership changes and expanded vocational offerings.

Australian Unity Limited reported robust FY2025 financial results, driven by strategic acquisitions and ongoing transformation efforts, returning to profitability with a $26.6 million net profit. The company is poised to complete its multi-year transformation by year-end and focus on growth amid rising demand for aged care and health services.

Nido Education Limited reported an 8% rise in Service EBITDA to $12.8 million for the first half of 2025, maintaining steady operational performance despite sector-wide occupancy challenges. The company declared a fully franked interim dividend of 1.5 cents per share, underscoring confidence in its growth strategy.

Australian Unity Limited reports a strong FY2025 financial turnaround with $136.2 million Adjusted EBITDA, driven by a multi-year transformation program focused on portfolio reshaping and technology integration.

GenusPlus Group Ltd has delivered record FY2025 financial results, driven by strong contract wins and strategic acquisitions, positioning itself as a key player in Australia’s energy transition. The company forecasts robust earnings growth for FY2026 backed by a $2 billion orderbook.

GenusPlus Group Ltd has reported a robust 36% increase in revenue and an 84% surge in net profit for FY2025, driven by strategic acquisitions and growth in the renewable energy sector. The company also declared a higher fully franked dividend, reflecting confidence in its expanding infrastructure footprint.

Imagion Biosystems reported a $1.66 million loss for the half-year ending June 2025 while progressing its MagSense® HER2 Imaging Agent towards a Phase 2 FDA trial and securing $3.5 million in new funding.

BPH Energy Limited reported a 49% increase in net profit for FY2025, driven by gains in its energy and biotech investments, while facing a pivotal Federal Court hearing over the renewal of the PEP-11 offshore gas exploration permit.

Nova Eye Medical has reported a record A$29.3 million in FY25 revenue, driven by sustained US growth and operational improvements, setting the stage for breakeven EBITDA in the first half of FY26.

Nova Eye Medical Limited reported a 25% increase in revenue to AUD 29.3 million for FY2025, driven by strong sales in its glaucoma surgical devices segment, yet posted a net loss after tax of AUD 9.1 million. The company raised AUD 6.2 million through a share placement to support growth initiatives.